Cerebrolysin
FPF-1070 Β· Cere Β· EVER Neuro Pharma
Standardised mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain. The most clinically validated neuroregenerative peptide mixture, with RCT data in stroke, vascular dementia, and Alzheimer's disease.
Want a personalised protocol?
Our AI generator builds a protocol tailored to your profile and goals.
Mechanism of Action
Multi-target: (1) Neurotrophic factor mimicry β activates BDNF, NGF, IGF-1, and CNTF receptor pathways β neuronal survival and synaptic plasticity; (2) Neurogenesis β promotes neural stem cell proliferation and differentiation in the hippocampus; (3) Anti-apoptotic β reduces excitotoxicity and mitochondrial dysfunction in injured neurons; (4) Metabolic β improves neuronal glucose utilisation and ATP production; (5) Anti-amyloid β reduces AΞ²42 aggregation and tau hyperphosphorylation in Alzheimer models.
Clinical Applications
- βAcute ischemic stroke β improves functional outcomes when started within 72 h (CEREBROLYSIN trial data)
- βVascular dementia β slows progression, improves MMSE and ADAS-cog in RCTs
- βAlzheimer's disease β modest cognitive stabilisation; best evidence as adjunct to AChEIs
- βTraumatic brain injury β accelerates neurological recovery
- βPost-stroke rehabilitation β extends neuroplasticity window
- βAge-related cognitive decline β off-label use for cognitive longevity
Dosing Protocol
Recommended Dosing
IV or IM only β not suitable for SC due to local tissue irritation. Acute neurological (stroke/TBI): 10β30 mL IV daily for 10β21 days. Cognitive decline/dementia: 5β10 mL IM or IV daily for 10β20 days, 2β4 courses per year. Must be diluted in 100 mL normal saline for IV infusion over 30β60 min. IM: undiluted or diluted, 5 mL max per injection site.Safety & Contraindications
Possible Side Effects
- β Fever and flu-like symptoms (most common β immune activation, especially first doses)
- β Agitation, insomnia, or dizziness (CNS activation β dose-dependent)
- β Nausea and GI discomfort
- β Injection site pain with IM administration
- β Rare: seizure (in patients with epilepsy or post-stroke β monitor closely)
- β Allergic reactions β porcine-derived product; caution in pork allergy
Contraindications
- βEpilepsy or active seizure disorder β risk of lowering seizure threshold
- βPork allergy
- βSevere renal impairment (amino acid load)
- βPregnancy
- βStatus epilepticus